Affymax CEO Arlene Morris said that the Therapeutic Discovery Project empowers small biotech companies, like Affymax, by providing needed capital to support breakthrough medical discovery, innovation and job creation and sustainability in the US.
"The funds we receive will provide additional support for the development of Hematide," Morris said.
Hematide/peginesatide is an investigational erythropoiesis-stimulating agent (ESA) that is being tested in clinical trials for the treatment of anemia associated with chronic renal failure (CRF).